We are live on ! Find out more
EC

Elmind Capital Portfolio holdings

AUM $398M
This Fund
S&P 500
This Quarter Est. Return
+20.37%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$398M
AUM Growth
+$45.8M
Cap. Flow
+$10.9M
Cap. Flow %
2.73%
Top 10 Hldgs %
66.6%
Holding
39
New
5
Increased
9
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$15.4M
2
RLAY icon
Relay Therapeutics
RLAY
+$13.5M
3
SMMT icon
Summit Therapeutics
SMMT
+$8.76M
4
INSM icon
Insmed
INSM
+$7.87M
5
PCVX icon
Vaxcyte
PCVX
+$7.38M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$20.6M
2
CGON icon
CG Oncology
CGON
+$19.7M
3
TYRA icon
Tyra Biosciences
TYRA
+$10.9M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.34M
5
MBX
MBX Biosciences
MBX
+$4.19M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
26
BioMarin Pharmaceuticals
BMRN
$12.6B
$2.69M 0.68%
47,000
– –
IMCR icon
27
Immunocore
IMCR
$1.89B
$2.58M 0.65%
81,143
+22,895
+39% +$677K
AMLX icon
28
Amylyx Pharmaceuticals
AMLX
$4.14B
$2.01M 0.51%
112,000
– –
ALEC icon
29
Alector
ALEC
$267M
$1.81M 0.45%
900,000
– –
SEPN
30
Septerna Inc
SEPN
$1.89B
$1.66M 0.42%
+49,444
New +$1.4M
DSGN icon
31
Design Therapeutics
DSGN
$954M
$1.56M 0.39%
107,900
-100,000
-48% -$1.25M
STRO icon
32
Sutro Biopharma
STRO
$353M
$1.06M 0.27%
+32,037
New +$999K
WVE icon
33
Wave Life Sciences
WVE
$1.02B
$1.03M 0.26%
177,846
– –
TYRA icon
34
Tyra Biosciences
TYRA
$1.56B
$639K 0.16%
20,000
-330,000
-94% -$10.9M
ENGN icon
35
enGene Therapeutics
ENGN
$128M
$363K 0.09%
210,000
– –
APLS
36
DELISTED
Apellis Pharmaceuticals
APLS
– –
-50,000
Closed -$2.01M
CGON icon
37
CG Oncology
CGON
$7B
– –
-291,800
Closed -$19.7M
EWTX icon
38
Edgewise Therapeutics
EWTX
$4.8B
– –
-10,000
Closed -$315K
KALV
39
DELISTED
KalVista Pharmaceuticals
KALV
– –
-1,021,300
Closed -$20.6M
1
2

Similar funds

FFS
Fischer Financial Services Harrisburg, Pennsylvania $398M AUM 22.91% 1-Year Est. Return
SFS
Stiles Financial Services Edina, Minnesota $398M AUM 55.89% 1-Year Est. Return
SIC
Shoker Investment Counsel Oxford, Ohio $398M AUM 39.01% 1-Year Est. Return
SIAS
Summit Investment Advisory Services Roseville, Minnesota $398M AUM 21.26% 1-Year Est. Return
HVP
Hudson Value Partners Palm Beach, Florida $399M AUM 48.26% 1-Year Est. Return
AC
Alfreton Capital Radlett, Hertfordshire, United Kingdom $399M AUM 20.53% 1-Year Est. Return
W
WorthPointe La Jolla, California $399M AUM 22.49% 1-Year Est. Return
CL
COWA LLC Tulsa, Oklahoma $399M AUM 25.74% 1-Year Est. Return

Elmind Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Elmind Capital held 39 positions worth $398M, up 13% from $352M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Elmind Capital's Q2 2026 filing shows 5 new, 9 increased, 6 reduced and 4 closed positions. Its largest new stake was Legend Biotech: 570,569 shares worth $16.5M. The largest sale was KalVista Pharmaceuticals, an estimated $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Elmind Capital's largest Q2 2026 buy was Legend Biotech: 570,569 shares worth $16.5M.
  • Elmind Capital added most to Relay Therapeutics in Q2 2026, an estimated $13.5M increase.
  • Elmind Capital's biggest Q2 2026 reduction was Tyra Biosciences, cutting an estimated $10.9M.
  • Elmind Capital fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $20.6M.
  • Elmind Capital's ten largest holdings make up 67% of its $398M portfolio in Q2 2026.
  • Elmind Capital opened 5 new positions and closed 4 in Q2 2026.
  • Elmind Capital's portfolio value rose 13% quarter-over-quarter to $398M.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.